Investing in Johnson & Johnson.
Johnson & Johnson has been a part of people's lives for 128 years and a valuable part of their investments for approximately 70 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.
During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.
Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 30 consecutive years of adjusted earnings increases; and 52 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 8.9 percent total return for investors compared to a 7.4 percent total return for the S&P 500.(1)
July 29, 2014
IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p
July 28, 2014
Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen's Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C
July 28, 2014
Ethicon Launches HARMINIC FOCUS®+ Shears With Adaptive Tissue Technology At Ifhnos/Ahns Scientific Meeting
July 15, 2014 at 8:30 AM ET
Johnson & Johnson Second Quarter 2014 Earnings Meeting and Webcast
Financial Quick Links
1. Data source - Bloomberg